Mohammed Alshalalfa

Mohammed Alshalalfa

Auto-generated profile, based on publicly available information

Mohammed Alshalalfa

Veracyte, Inc South San Francisco California USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJoanna Cyrta
Joanna Cyrta
AAAnke Augspach
Anke Augspach
MFMaria Rosaria De Filippo
Maria Rosaria De Filippo
DPDavide Prandi
Davide Prandi
PTPhillip Thienger
Phillip Thienger
MRMark A. Rubin
Mark A. Rubin
Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes resistant and requires more potent therapies. One mechanism of resistance observed in around 10–20% of these patients is lineage plasticity, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC. Using large patient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1) overexpression is associated with aggressive disease. We also show that SWI/SNF complexes interact with different lineage-specific factors in NEPC compared to prostate adenocarcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage plasticity, which may also be relevant for other solid tumors.

15 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAyesha A Shafi
Ayesha A Shafi
CMChris M. McNair
Chris M. McNair
JMJennifer J. McCann
Jennifer J. McCann
MAMohammed Alshalalfa
Mohammed Alshalalfa
ASAnton Shostak
Anton Shostak
KKKaren E. Knudsen
Karen E. Knudsen
Mechanisms regulating DNA repair processes remain incompletely defined. Here, the circadian factor CRY1, an evolutionally conserved transcriptional coregulator, is identified as a tumor specific regulator of DNA repair. Key findings demonstrate that CRY1 expression is androgen-responsive and associates with poor outcome in prostate cancer. Functional studies and first-in-field mapping of the CRY1 cistrome and transcriptome reveal that CRY1 regulates DNA repair and the G2/M transition. DNA damage stabilizes CRY1 in cancer (in vitro, in vivo, and human tumors ex vivo), which proves critical for efficient DNA repair. Further mechanistic investigation shows that stabilized CRY1 temporally regulates expression of genes required for homologous recombination. Collectively, these findings reveal that CRY1 is hormone-induced in tumors, is further stabilized by genomic insult, and promotes DNA repair and cell survival through temporal transcriptional regulation. These studies identify the circadian factor CRY1 as pro-tumorigenic and nominate CRY1 as a new therapeutic target.

21 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNeha Singh
Neha Singh
VRVarune R. Ramnarine
Varune R. Ramnarine
JSJin H. Song
Jin H. Song
RPRitu Pandey
Ritu Pandey
SPSathish K. R. Padi
Sathish K. R. Padi
AKAndrew S. Kraft
Andrew S. Kraft
Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (PCa) arising either de novo or from transdifferentiated prostate adenocarcinoma following androgen deprivation therapy (ADT). Extensive computational analysis has identified a high degree of association between the long noncoding RNA (lncRNA) H19 and NEPC, with the longest isoform highly expressed in NEPC. H19 regulates PCa lineage plasticity by driving a bidirectional cell identity of NE phenotype (H19 overexpression) or luminal phenotype (H19 knockdown). It contributes to treatment resistance, with the knockdown of H19 re-sensitizing PCa to ADT. It is also essential for the proliferation and invasion of NEPC. H19 levels are negatively regulated by androgen signaling via androgen receptor (AR). When androgen is absent SOX2 levels increase, driving H19 transcription and facilitating transdifferentiation. H19 facilitates the PRC2 complex in regulating methylation changes at H3K27me3/H3K4me3 histone sites of AR-driven and NEPC-related genes. Additionally, this lncRNA induces alterations in genome-wide DNA methylation on CpG sites, further regulating genes associated with the NEPC phenotype. Our clinical data identify H19 as a candidate diagnostic marker and predictive marker of NEPC with elevated H19 levels associated with an increased probability of biochemical recurrence and metastatic disease in patients receiving ADT. Here we report H19 as an early upstream regulator of cell fate, plasticity, and treatment resistance in NEPC that can reverse/transform cells to a treatable form of PCa once therapeutically deactivated.

3 June 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
WRWalter Rayford
Walter Rayford
ABAlp Tuna Beksac
Alp Tuna Beksac
JAJordan Alger
Jordan Alger
MAMohammed Alshalalfa
Mohammed Alshalalfa
MAMohsen Ahmed
Mohsen Ahmed
ATAsh Tewari
Ash Tewari
Racial disparities in prostate cancer have not been well characterized on a genomic level. Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 African-American men (AAM) and 556 European-American men (EAM)) who underwent radical prostatectomy. Comparative analyses between the race groups were conducted at the clinical, genomic, pathway, molecular subtype, and prognostic levels. The EAM group had increased ERG (P < 0.001) and ETS (P = 0.02) expression, decreased SPINK1 expression (P < 0.001), and basal-like (P < 0.001) molecular subtypes. After adjusting for confounders, the AAM group was associated with higher expression of CRYBB2, GSTM3, and inflammation genes (IL33, IFNG, CCL4, CD3, ICOSLG), and lower expression of mismatch repair genes (MSH2, MSH6) (p < 0.001 for all). At the pathway level, the AAM group had higher expression of genes sets related to the immune response, apoptosis, hypoxia, and reactive oxygen species. EAM group was associated with higher levels of fatty acid metabolism, DNA repair, and WNT/beta-catenin signaling. Based on cell lines data, AAM were predicted to have higher potential response to DNA damage. In conclusion, biological characteristics of prostate tumor were substantially different in AAM when compared to EAM.

19 October 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JAJuan M. Arriaga
Juan M. Arriaga
SPSukanya Panja
Sukanya Panja
MAMohammed Alshalalfa
Mohammed Alshalalfa
JZJunfei Zhao
Junfei Zhao
MZMin Zou
Min Zou
CACory Abate-Shen
Cory Abate-Shen

19 March 2022 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
NSNishwant Swami
Nishwant Swami
YBYefri A. Baez
Yefri A. Baez
IFIdalid Franco
Idalid Franco
TNTiffany Nguyen
Tiffany Nguyen
KMKarthik Meiyappan
Karthik Meiyappan
EDEdward Christopher Dee
Edward Christopher Dee